Skip to main content
Top
Published in: Journal of Neurology 11/2012

01-11-2012 | Original Communication

Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson’s disease

Authors: Helen Ling, Igor Petrovic, Brian L. Day, Andrew J. Lees

Published in: Journal of Neurology | Issue 11/2012

Login to get access

Abstract

We report a 53-year-old patient with Parkinson’s disease who complained of transient worsening of motor symptoms after smoking a tobacco cigarette. She had been a chronic smoker of one packet of cigarettes a day for over 20 years. We objectively assessed her motor performance including repetitive finger tapping (RFT) speed using 3D kinematic recordings, timed finger tapping test (TFT) and Unified Parkinson’s Disease Rating Scale (UPDRS) III before and after the administration of nicotine, and with and without levodopa. Nicotine was delivered by either smoking a cigarette or by intranasal nicotine spray. Without levodopa, acute deterioration in RFT speed was observed 10 min after both routes of nicotine administration. With levodopa, there was acute deterioration in RFT speed after smoking cigarette, followed by a delayed rebound improvement. However, the administration of nicotine spray led to immediate and sustained motor improvement without initial deterioration. UPDRS III and TFT showed similar trends of acute motor deterioration after either smoking or use of the spray without intake of levodopa. Transient motor worsening after smoking tobacco has been previously reported in only one patient with Parkinson’s disease. The objective findings of acute motor deterioration following both cigarette smoking and nicotine spray administration suggest that nicotine might be the cause of the negative motor effects in this patient. Similar changes were not observed after the administration of placebo intranasal spray. At low dose or beginning of dose, nicotine induces sub-threshold stimulation of dopamine release, which selectively activates the pre-synaptic D2 autoreceptors, leading to transient motor worsening. The potential mechanisms of the additive effect of levodopa and nicotine and paradoxical motor improvement after administration of high-dose nicotine via intranasal nicotine spray are also discussed.
Appendix
Available only for authorised users
Literature
2.
go back to reference Benoit-Marand M, Borrelli E, Gonon F (2001) Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J Neurosci 21:9134–9141PubMed Benoit-Marand M, Borrelli E, Gonon F (2001) Inhibition of dopamine release via presynaptic D2 receptors: time course and functional characteristics in vivo. J Neurosci 21:9134–9141PubMed
3.
go back to reference Clemens P, Baron JA, Coffey D, Reeves A (1995) The short-term effect of nicotine chewing gum in patients with Parkinson’s disease. Psychopharmacology 117:253–256PubMedCrossRef Clemens P, Baron JA, Coffey D, Reeves A (1995) The short-term effect of nicotine chewing gum in patients with Parkinson’s disease. Psychopharmacology 117:253–256PubMedCrossRef
4.
go back to reference Colosimo C, Inghilleri M (2012) A further case of nicotine sensitivity in multiple system atrophy. Clin Neuropharmacol 35:51–52PubMedCrossRef Colosimo C, Inghilleri M (2012) A further case of nicotine sensitivity in multiple system atrophy. Clin Neuropharmacol 35:51–52PubMedCrossRef
5.
go back to reference Dogu O, Johnson J, Hernandez D, Hanson M, Hardy J, Apaydin H, Ozekmekci S, Sevim S, Gwinn-Hardy K, Singleton A (2004) A consanguineous Turkish family with early onset Parkinson’s disease and an exon 4 parkin deletion. Mov Disord 19:812–816PubMedCrossRef Dogu O, Johnson J, Hernandez D, Hanson M, Hardy J, Apaydin H, Ozekmekci S, Sevim S, Gwinn-Hardy K, Singleton A (2004) A consanguineous Turkish family with early onset Parkinson’s disease and an exon 4 parkin deletion. Mov Disord 19:812–816PubMedCrossRef
6.
go back to reference Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, Poewe W (1999) Worsening of motor performance in patients with Parkinson’s disease following transdermal nicotine administration. Mov Disord 14:1011–1013PubMedCrossRef Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, Poewe W (1999) Worsening of motor performance in patients with Parkinson’s disease following transdermal nicotine administration. Mov Disord 14:1011–1013PubMedCrossRef
7.
go back to reference Fagerstrom KO, Pomerleau O, Giordani B, Stelson F (1994) Nicotine may relieve symptoms of Parkinson’s disease. Psychopharmacology 116:117–119PubMedCrossRef Fagerstrom KO, Pomerleau O, Giordani B, Stelson F (1994) Nicotine may relieve symptoms of Parkinson’s disease. Psychopharmacology 116:117–119PubMedCrossRef
8.
go back to reference Graham JG, Oppenheimer DR (1969) Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 32:28–34PubMedCrossRef Graham JG, Oppenheimer DR (1969) Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 32:28–34PubMedCrossRef
9.
go back to reference Hanagasi HA, Lees A, Johnson JO, Singleton A, Emre M (2007) Smoking-responsive juvenile-onset Parkinsonism. Mov Disord 22:115–119PubMedCrossRef Hanagasi HA, Lees A, Johnson JO, Singleton A, Emre M (2007) Smoking-responsive juvenile-onset Parkinsonism. Mov Disord 22:115–119PubMedCrossRef
10.
go back to reference Ishikawa A, Miyatake T (1993) Effects of smoking in patients with early onset Parkinson’s disease. J Neurol Sci 117:28–32PubMedCrossRef Ishikawa A, Miyatake T (1993) Effects of smoking in patients with early onset Parkinson’s disease. J Neurol Sci 117:28–32PubMedCrossRef
11.
go back to reference Kelton MC, Kahn HJ, Conrath CL, Newhouse PA (2000) The effects of nicotine on Parkinson’s disease. Brain Cogn 43:274–282PubMed Kelton MC, Kahn HJ, Conrath CL, Newhouse PA (2000) The effects of nicotine on Parkinson’s disease. Brain Cogn 43:274–282PubMed
12.
go back to reference Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A, Bedard MA (2004) Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 28:31–39PubMedCrossRef Lemay S, Chouinard S, Blanchet P, Masson H, Soland V, Beuter A, Bedard MA (2004) Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 28:31–39PubMedCrossRef
13.
go back to reference Marshall J, Schnieden H (1966) Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor. J Neurol Neurosurg Psychiatry 29:214–218PubMedCrossRef Marshall J, Schnieden H (1966) Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor. J Neurol Neurosurg Psychiatry 29:214–218PubMedCrossRef
14.
go back to reference Merello M, Lees AJ (1992) Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:1024–1026PubMedCrossRef Merello M, Lees AJ (1992) Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:1024–1026PubMedCrossRef
15.
go back to reference Nishimura H, Tachibana H, Okuda B, Sugita M (1997) Transient worsening of Parkinson’s disease after cigarette smoking. Intern Med 36:651–653PubMedCrossRef Nishimura H, Tachibana H, Okuda B, Sugita M (1997) Transient worsening of Parkinson’s disease after cigarette smoking. Intern Med 36:651–653PubMedCrossRef
16.
go back to reference Paisan-Ruiz C, Guevara R, Federoff M, Hanagasi H, Sina F, Elahi E, Schneider SA, Schwingenschuh P, Bajaj N, Emre M, Singleton AB, Hardy J, Bhatia KP, Brandner S, Lees AJ, Houlden H (2010) Early onset l-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord 25:1791–1800PubMedCrossRef Paisan-Ruiz C, Guevara R, Federoff M, Hanagasi H, Sina F, Elahi E, Schneider SA, Schwingenschuh P, Bajaj N, Emre M, Singleton AB, Hardy J, Bhatia KP, Brandner S, Lees AJ, Houlden H (2010) Early onset l-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord 25:1791–1800PubMedCrossRef
17.
18.
go back to reference Schneider JS, Van Velson M, Menzaghi F, Lloyd GK (1998) Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann Neurol 43:311–317PubMedCrossRef Schneider JS, Van Velson M, Menzaghi F, Lloyd GK (1998) Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann Neurol 43:311–317PubMedCrossRef
19.
go back to reference Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P (2001) Transdermal nicotine in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Neurology 57:1032–1035PubMedCrossRef Vieregge A, Sieberer M, Jacobs H, Hagenah JM, Vieregge P (2001) Transdermal nicotine in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Neurology 57:1032–1035PubMedCrossRef
20.
go back to reference Villafane G, Cesaro P, Rialland A, Baloul S, Azimi S, Bourdet C, Le Houezec J, Macquin-Mavier I, Maison P (2007) Chronic high dose transdermal nicotine in Parkinson’s disease: an open trial. Eur J Neurol 14:1313–1316PubMedCrossRef Villafane G, Cesaro P, Rialland A, Baloul S, Azimi S, Bourdet C, Le Houezec J, Macquin-Mavier I, Maison P (2007) Chronic high dose transdermal nicotine in Parkinson’s disease: an open trial. Eur J Neurol 14:1313–1316PubMedCrossRef
21.
go back to reference Wonnacott S, Barik J, Dickinson J, Jones IW (2006) Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. J Mol Neurosci 30:137–140PubMedCrossRef Wonnacott S, Barik J, Dickinson J, Jones IW (2006) Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. J Mol Neurosci 30:137–140PubMedCrossRef
Metadata
Title
Smoking-induced transient motor deterioration in a levodopa-treated patient with Parkinson’s disease
Authors
Helen Ling
Igor Petrovic
Brian L. Day
Andrew J. Lees
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Journal of Neurology / Issue 11/2012
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6515-5

Other articles of this Issue 11/2012

Journal of Neurology 11/2012 Go to the issue